November 3, 2025 — Leads & Copy — Hologic, Inc. (Nasdaq: HOLX) reported its fiscal fourth-quarter results, with revenue up 6.2% to $1,049.5 million. GAAP diluted EPS was $0.83, and non-GAAP diluted EPS was $1.13.
The company announced on October 21, 2025, that it will be acquired by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share. Total organic revenue excluding COVID-19 related revenue, divested businesses, and acquired businesses increased 6.2%. GAAP diluted EPS rose 9.2%, while non-GAAP EPS increased 11.9%.
Diagnostics revenue grew 2.4%, driven by higher U.S. molecular diagnostics sales. Breast Health revenue increased 4.8%, fueled by interventional product sales and the inclusion of Endomagnetics. Surgical revenue grew 10.2%, driven by MyoSure, Fluent, and the Gynesonics business.
Cash flow from operations was $355.1 million. Hologic received FDA clearance and CE marking for its Panther Fusion Gastrointestinal Bacterial and Expanded Bacterial Assays.
Given Hologic’s agreement to be acquired by Blackstone and TPG, the Company is not providing annual or quarterly financial guidance for fiscal year 2026, and will not host a conference call to discuss its fourth quarter 2025 financial results.
Hologic ended the quarter with $1.96 billion in cash and cash equivalents.
Hologic, Inc. is focused on improving women’s health and well-being through early detection and treatment.
Contact Hologic investor relations at investors@hologic.com or calling 858-410-8904.
Source: Hologic, Inc.
